Vectorite Biomedical

Vectorite Biomedical CapEx/D&A

The CapEx to Depreciation Ratio of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 0.24. In the previous year, CapEx to Depreciation Ratio was 0.08 — a change of 185.61% (higher).

CapEx/D&A

0.24

YoY

185.61%

Last updated:

CapEx to Depreciation Ratio of Vectorite Biomedical is 2021 0.24 . CapEx to Depreciation Ratio of Vectorite Biomedical was 2020 0.08 . It decreases by 185.61% higher compared to the previous year.

The Vectorite Biomedical CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2018
21.01 TWD
Jan 1, 2019
0.46 TWD
Jan 1, 2020
0.08 TWD
Jan 1, 2021
0.24 TWD
The Vectorite Biomedical CapEx/D&A history
YEARCapEx/D&AYoY
0.24+185.61%
0.08-82.06%
0.46-97.80%
21.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

CapEx to Depreciation Ratio of Vectorite Biomedical is 0.24 in 2021.

CapEx to Depreciation Ratio of Vectorite Biomedical changed from 0.08 to 0.24, representing a 185.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectorite Biomedical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectorite Biomedical